search
Back to results

RAFTLIN-1 Levels in Axial Spondyloarthritis and Psoriatic Arthritis

Primary Purpose

Axial Spondyloarthritis, Psoriatic Arthritis

Status
Completed
Phase
Not Applicable
Locations
Turkey
Study Type
Interventional
Intervention
serum raftlin-1 protein levels
Sponsored by
Bezmialem Vakif University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional diagnostic trial for Axial Spondyloarthritis focused on measuring Axial Spondyloarthritis, Psoriatic Arthritis, Raftlin-1

Eligibility Criteria

18 Years - 65 Years (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria: Being aged 18 to 65 Meeting ASAS axial spondyloarthritis classification criteria Meeting The CASPAR (ClASsification criteria for Psoriatic ARthritis) criteria Exclusion Criteria: Having a burn or a wound Active infection systemic inflammatory disease (Type 1 DM, autoimmune thyroiditis, other inflammatory rheumatic conditions etc.) Pregnancy Malignancy severe cognitive function disorder

Sites / Locations

  • Bezmialem University

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Active Comparator

Active Comparator

Placebo Comparator

Arm Label

Psoriatic arthritis

Axial spondyloarthritis

Healthy controls

Arm Description

Patients meeting the CASPAR (ClASsification criteria for Psoriatic ARthritis) criteria

Patients meeting the ASAS classification criteria for axial spondyloarthritis

Healthy people who do not have inflammatory conditions.

Outcomes

Primary Outcome Measures

Bath Ankylosing Spondylitis Disease Activity Index(BASDAI)
This questionnaire evaluates the disease activity level in patients with AS. The BASDAI consists of a 0 - 10 scale measuring discomfort, pain, and fatigue (0 being no problem and 10 being the worst problem) in response to six questions asked of the patient pertaining to the five major symptoms of AS. The final score varies between 0 and 10.
Bath Ankylosing Spondylitis Disease Activity Index(BASFI)
This questionnaire evaluates the functionality in patients with AS. The ten questions that comprise the BASFI were chosen with input from patients with AS. The first 8 questions evaluate activities related to functional anatomical limitations due to the course of this inflammatory disease. The final 2 questions evaluate the patients' ability to cope with everyday life. A visual analogue scale (with 0 being "easy" and 10 "impossible) is used to answer the questions on the test. The final score varies between 0 and 10.
The Ankylosing Spondylitis Disease Activity Score (ASDAS)
AS Disease Activity Score has been developed by taking into account total back pain (Bath Ankylosing Spondylitis Disease Activity Index [BASDAI] question 2), patient global evaluation, peripheral joint pain or swelling (BASDAI question 3), duration of morning stiffness (BASDAI question 6), and C-reactive protein (CRP) (or erythrocyte sedimentation rate [ESR] if CRP is not available). The cutoffs between the disease activity states are inactive disease ≤1.3, moderate 1.3-2.0, high 2.1-3.5, and very high ≥3.5. The ASDAS cutoff for clinically important improvement between examinations is ≥1.1, and the cutoff for a major improvement is ≥2.0.
Bath Ankylosing Spondylitis Metrology Index(BASMI)
Bath Ankylosing Spondylitis Metrology Index, a combined index to assess the spinal mobility. It evaluates the patients regarding cervical rotation, tragus-to-wall distance, lumbar flexion, lumbar lateral flexion and intermalleolar distance. The total score varies between 5 to 15 in patients with ankylosing spondylitis
Disease Activity Index for Psoriatic Arthritis (DAPSA)
DAPSA includes a 68/66 joint count summed with a patient global, patient pain score, and C- reactive protein level. The DAPSA provides a continuous score of arthritis activity and has validated cut points for remission (< 4) and low disease activity (< 14).
Spondyloarthritis Research Consortium of Canada Enthesitis Index(SPARCC Enthesitis Index)
The Spondyloarthritis Research Consortium of Canada (SPARCC) index, developed in Canada by Walter Maksymowych and others, was developed in patients with spondyloarthritis and includes assessment of 18 sites for tenderness. The total score is 16, because the distal patella and tibial tuberosity, in close proximity, are considered as one site. The core is between 0 and 16.
Health Assessment Questionnaire (HAQ)
The Health assessment questionnaire (HAQ) is a questionnaire for the assessment of disability in an individual. The patients report the amount of difficulty they have in performing eight daily living activities. Each question asks on a scale ranging from 0 to 3 if the categories can be performed without any difficulty (scale 0) up to cannot be done at all (scale 3). The final score varies between 0 and 3.
numeric rating scale (rest, movement)
Self reported pain scored between 0 (minimum)-10 (maximum). Higher scores represent a worse outcome.

Secondary Outcome Measures

Full Information

First Posted
March 5, 2023
Last Updated
July 10, 2023
Sponsor
Bezmialem Vakif University
search

1. Study Identification

Unique Protocol Identification Number
NCT05771389
Brief Title
RAFTLIN-1 Levels in Axial Spondyloarthritis and Psoriatic Arthritis
Official Title
Correlation of RAFTLIN-1 Levels and Clinical Parameters in Axial Spondyloarthritis and Psoriatic Arthritis
Study Type
Interventional

2. Study Status

Record Verification Date
July 2023
Overall Recruitment Status
Completed
Study Start Date
March 21, 2023 (Actual)
Primary Completion Date
July 9, 2023 (Actual)
Study Completion Date
July 9, 2023 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Bezmialem Vakif University

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Unlike other rheumatic diseases, acute phase reactants such as C-reactive protein and erythrocyte sedimentation rate are not diagnostic for patients with Spondyloarthropathies (SpA). Also, it is not possible to monitor disease activity with these tests. On the other hand, HLA-B27 positivity varies between races, and 8% of the normal population is HLA-B27 positive. In this manner, new biomarkers for endorsing the diagnosis and monitoring the disease activity are necessary. Acute phase reactants are not sensitive for diagnosing and assessing disease activity. This may lead to a diagnostic delay of up to 9 years. The investigators hypothesize that Raftlin-1, thought to have a regulatory role in TH17 function and IL-17-mediated immunity, may be a novel biomarker for showing inflammation-related clinical features.
Detailed Description
Unlike other rheumatic diseases, acute phase reactants such as C-reactive protein and erythrocyte sedimentation rate are not diagnostic for patients with Spondyloarthropathies (SpA). Also, it is not possible to monitor disease activity with these tests. On the other hand, HLA-B27 positivity varies between races, and 8% of the normal population is HLA-B27 positive. In this manner, new biomarkers for endorsing the diagnosis and monitoring the disease activity are necessary. In recent years Raftlin, a significant lipid raft protein responsible for transmembrane signal transmission, was found. It has been discovered that the Raftlin protein has two subtypes (Raftlin-1 and Raftlin-2), and in transgenic mice without RAFTLIN genes, T-cell-dependent immunity has been altered. Cytokine production, especially IL-17, is diminished in T cells with the lack of Raftlin protein, while it is increased in T cells, including transgenic Raftlin. This condition is associated with TCR-related signaling pathways. Particularly, Lck protein occurrence in lipid raft is increased with Raftlin overexpression, while it is diminished with absence. Regarding this, Raftlin is thought to modulate TCR signaling, thus altering the T-cell mediated immunity. Acute phase reactants are not sensitive for diagnosing and assessing disease activity. This may lead to a diagnostic delay of up to 9 years. The investigators hypothesize that Raftlin-1, thought to have a regulatory role in TH17 function and IL-17-mediated immunity, may be a novel biomarker for showing inflammation-related clinical features.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Axial Spondyloarthritis, Psoriatic Arthritis
Keywords
Axial Spondyloarthritis, Psoriatic Arthritis, Raftlin-1

7. Study Design

Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
119 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Psoriatic arthritis
Arm Type
Active Comparator
Arm Description
Patients meeting the CASPAR (ClASsification criteria for Psoriatic ARthritis) criteria
Arm Title
Axial spondyloarthritis
Arm Type
Active Comparator
Arm Description
Patients meeting the ASAS classification criteria for axial spondyloarthritis
Arm Title
Healthy controls
Arm Type
Placebo Comparator
Arm Description
Healthy people who do not have inflammatory conditions.
Intervention Type
Diagnostic Test
Intervention Name(s)
serum raftlin-1 protein levels
Intervention Description
Lipid raft linker 1 (Raftlin-1) is a protein which enables double-stranded RNA binding activity. It is involved in T cell receptor signaling pathway; membrane raft assembly; and positive regulation of growth rate. It acts upstream of or within dsRNA transport; response to exogenous dsRNA; and toll-like receptor signaling pathway. Located in endosome; membrane raft; and plasma membrane.
Primary Outcome Measure Information:
Title
Bath Ankylosing Spondylitis Disease Activity Index(BASDAI)
Description
This questionnaire evaluates the disease activity level in patients with AS. The BASDAI consists of a 0 - 10 scale measuring discomfort, pain, and fatigue (0 being no problem and 10 being the worst problem) in response to six questions asked of the patient pertaining to the five major symptoms of AS. The final score varies between 0 and 10.
Time Frame
1 day
Title
Bath Ankylosing Spondylitis Disease Activity Index(BASFI)
Description
This questionnaire evaluates the functionality in patients with AS. The ten questions that comprise the BASFI were chosen with input from patients with AS. The first 8 questions evaluate activities related to functional anatomical limitations due to the course of this inflammatory disease. The final 2 questions evaluate the patients' ability to cope with everyday life. A visual analogue scale (with 0 being "easy" and 10 "impossible) is used to answer the questions on the test. The final score varies between 0 and 10.
Time Frame
1 day
Title
The Ankylosing Spondylitis Disease Activity Score (ASDAS)
Description
AS Disease Activity Score has been developed by taking into account total back pain (Bath Ankylosing Spondylitis Disease Activity Index [BASDAI] question 2), patient global evaluation, peripheral joint pain or swelling (BASDAI question 3), duration of morning stiffness (BASDAI question 6), and C-reactive protein (CRP) (or erythrocyte sedimentation rate [ESR] if CRP is not available). The cutoffs between the disease activity states are inactive disease ≤1.3, moderate 1.3-2.0, high 2.1-3.5, and very high ≥3.5. The ASDAS cutoff for clinically important improvement between examinations is ≥1.1, and the cutoff for a major improvement is ≥2.0.
Time Frame
1 day
Title
Bath Ankylosing Spondylitis Metrology Index(BASMI)
Description
Bath Ankylosing Spondylitis Metrology Index, a combined index to assess the spinal mobility. It evaluates the patients regarding cervical rotation, tragus-to-wall distance, lumbar flexion, lumbar lateral flexion and intermalleolar distance. The total score varies between 5 to 15 in patients with ankylosing spondylitis
Time Frame
1 day
Title
Disease Activity Index for Psoriatic Arthritis (DAPSA)
Description
DAPSA includes a 68/66 joint count summed with a patient global, patient pain score, and C- reactive protein level. The DAPSA provides a continuous score of arthritis activity and has validated cut points for remission (< 4) and low disease activity (< 14).
Time Frame
1 day
Title
Spondyloarthritis Research Consortium of Canada Enthesitis Index(SPARCC Enthesitis Index)
Description
The Spondyloarthritis Research Consortium of Canada (SPARCC) index, developed in Canada by Walter Maksymowych and others, was developed in patients with spondyloarthritis and includes assessment of 18 sites for tenderness. The total score is 16, because the distal patella and tibial tuberosity, in close proximity, are considered as one site. The core is between 0 and 16.
Time Frame
1 day
Title
Health Assessment Questionnaire (HAQ)
Description
The Health assessment questionnaire (HAQ) is a questionnaire for the assessment of disability in an individual. The patients report the amount of difficulty they have in performing eight daily living activities. Each question asks on a scale ranging from 0 to 3 if the categories can be performed without any difficulty (scale 0) up to cannot be done at all (scale 3). The final score varies between 0 and 3.
Time Frame
1 day
Title
numeric rating scale (rest, movement)
Description
Self reported pain scored between 0 (minimum)-10 (maximum). Higher scores represent a worse outcome.
Time Frame
1 day

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Being aged 18 to 65 Meeting ASAS axial spondyloarthritis classification criteria Meeting The CASPAR (ClASsification criteria for Psoriatic ARthritis) criteria Exclusion Criteria: Having a burn or a wound Active infection systemic inflammatory disease (Type 1 DM, autoimmune thyroiditis, other inflammatory rheumatic conditions etc.) Pregnancy Malignancy severe cognitive function disorder
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Ozan Volkan Yurdakul, Assoc. Prof.
Organizational Affiliation
Bezmialem University
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Mert Kara, MD
Organizational Affiliation
Bezmialem University
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Ömer Faruk Özer, Assoc. Prof.
Organizational Affiliation
Bezmialem University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Bezmialem University
City
Istanbul
Country
Turkey

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
19248087
Citation
Rudwaleit M, Haibel H, Baraliakos X, Listing J, Marker-Hermann E, Zeidler H, Braun J, Sieper J. The early disease stage in axial spondylarthritis: results from the German Spondyloarthritis Inception Cohort. Arthritis Rheum. 2009 Mar;60(3):717-27. doi: 10.1002/art.24483.
Results Reference
background
PubMed Identifier
12805216
Citation
Saeki K, Miura Y, Aki D, Kurosaki T, Yoshimura A. The B cell-specific major raft protein, Raftlin, is necessary for the integrity of lipid raft and BCR signal transduction. EMBO J. 2003 Jun 16;22(12):3015-26. doi: 10.1093/emboj/cdg293.
Results Reference
background
PubMed Identifier
19414744
Citation
Saeki K, Fukuyama S, Ayada T, Nakaya M, Aki D, Takaesu G, Hanada T, Matsumura Y, Kobayashi T, Nakagawa R, Yoshimura A. A major lipid raft protein raftlin modulates T cell receptor signaling and enhances th17-mediated autoimmune responses. J Immunol. 2009 May 15;182(10):5929-37. doi: 10.4049/jimmunol.0802672.
Results Reference
background

Learn more about this trial

RAFTLIN-1 Levels in Axial Spondyloarthritis and Psoriatic Arthritis

We'll reach out to this number within 24 hrs